Results
tumor
DISEASE PROGRESSION, TUMOR
Between October 20, 2016 and October 10, 2019, 41 patients were randomly assigned to either C plus olaparib (Consort diagram.Patient and tumor characteristics at baseline
Overall, 37 patients (94.9%) underwent a second biopsy/surgery. One patient treated with D-Olaparib refused to undergo surgery, whereas in one additional patient the tumor was assessed as unresectable due to disease progression following treatment with D-Olaparib. Treatment completion was achieved in 31 of 34 treated patients (91.2%) [12 in the C-Olaparib group (100%), 10 in Olaparib only (100%), and 9 in the D-Olaparib treatment group (75%)]. Treatment discontinuation was noted in 2 patients who received D-Olaparib due to disease progression (